IN-VITRO EVALUATION OF DIFFERENT AVAILABLE BRANDS OF DEXLANSOPRAZOLE MR CAPSULES | Zendy

Halima Sadia | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

IN-VITRO EVALUATION OF DIFFERENT AVAILABLE BRANDS OF DEXLANSOPRAZOLE MR CAPSULES

Author(s) -

Halima Sadia

Publication year - 2020

Publication title -

journal of applied pharmacy

Language(s) - English

Resource type - Journals

ISSN - 1920-4159

DOI - 10.21065/19204159.12.11

Subject(s) - heartburn , gastroenterology , medicine , eosinophilic esophagitis , nerd , gerd , stomach , proton pump inhibitor , reflux esophagitis , ranitidine , pharmacology , reflux , disease

Dexlansoprazole delayed release is a newly developed class of Proton Pump Inhibitor (PPI). The drug is effective in the treatment of erosive esophagitis, maintenance of eosinophilic esophagitis and relief of heartburn. Additionally, it is also beneficial in the treatment of heartburn with symptomatic gastroesophageal reflux disease. The drug offers the advantage of no dosage adjustment in patients with hepatic impairment. Dexlansoprazole inhibits the stomach acid secrection by specific inhibition of the hydrogen-potassium–ATPase in parietal cells of stomach.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research